Parkinson Disease — Peer Partners to Improve Physical Activity in Older Latino and Latina Adults With Parkinson's Disease.
Citation(s)
Alberts JL, Rosenfeldt AB The Universal Prescription for Parkinson's Disease: Exercise. J Parkinsons Dis. 2020;10(s1):S21-S27. doi: 10.3233/JPD-202100.
Barcelona de Mendoza V, Damio G Evaluation of a culturally appropriate peer coaching program for smoking cessation. Public Health Nurs. 2018 Nov;35(6):541-550. doi: 10.1111/phn.12542. Epub 2018 Sep 14.
Bushnell DM, Martin ML Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res. 1999 Jun;8(4):345-50. doi: 10.1023/a:1008979705027.
Colon-Semenza C, Latham NK, Quintiliani LM, Ellis TD Peer Coaching Through mHealth Targeting Physical Activity in People With Parkinson Disease: Feasibility Study. JMIR Mhealth Uhealth. 2018 Feb 15;6(2):e42. doi: 10.2196/mhealth.8074.
Crespo CJ, Smit E, Andersen RE, Carter-Pokras O, Ainsworth BE Race/ethnicity, social class and their relation to physical inactivity during leisure time: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Prev Med. 2000 Jan;18(1):46-53. doi: 10.1016/s0749-3797(99)00105-1.
Griffith DM, Bergner EM, Cornish EK, McQueen CM Physical Activity Interventions With African American or Latino Men: A Systematic Review. Am J Mens Health. 2018 Jul;12(4):1102-1117. doi: 10.1177/1557988318763647. Epub 2018 Mar 20.
Ige-Elegbede J, Pilkington P, Gray S, Powell J Barriers and facilitators of physical activity among adults and older adults from Black and Minority Ethnic groups in the UK: A systematic review of qualitative studies. Prev Med Rep. 2019 Jul 13;15:100952. doi: 10.1016/j.pmedr.2019.100952. eCollection 2019 Sep.
Kroenke K, Spitzer RL, Williams JB The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
Lima LO, Rodrigues-de-Paula F Recruitment rate, feasibility and safety of power training in individuals with Parkinson's disease: a proof-of-concept study. Braz J Phys Ther. 2013 Jan-Feb;17(1):49-56. doi: 10.1590/s1413-35552012005000069. English, Portuguese.
Mendoza-Vasconez AS, Marquez B, Benitez TJ, Marcus BH Psychometrics of the self-efficacy for physical activity scale among a Latina women sample. BMC Public Health. 2018 Sep 5;18(1):1097. doi: 10.1186/s12889-018-5998-0.
Noroozi A, Ghofranipour F, Heydarnia AR, Nabipour I, Shokravi FA Validity and reliability of the social support scale for exercise behavior in diabetic women. Asia Pac J Public Health. 2011 Sep;23(5):730-41. doi: 10.1177/1010539509357342. Epub 2010 May 10.
Rogers G, Davies D, Pink J, Cooper P Parkinson's disease: summary of updated NICE guidance. BMJ. 2017 Jul 27;358:j1951. doi: 10.1136/bmj.j1951. No abstract available. Erratum In: BMJ. 2019 Feb 28;364:l961.
Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84. doi: 10.1136/jnnp.2005.075929.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.